• Faculty of Clinical Research (FCR)
  • Global accredited training & certification provider cleanindia
  • Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India.
  • ApprovedTraining Partner of Food Safety and Standards Authority of India (FSSAI)
  • An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India
  • Empanelled under Ministry of Horticulture and Food Processing, Govt. of Uttar Pradesh
  • Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC) set up by National Skill Development Corporation (NSDC)
  • Conferred with QUALITY COUNCIL OF INDIA (QCI) – D.L. SHAH NATIONAL QUALITY AWARD & ASSOCHAM Services Excellence Award 2017
  • Trusted by organizations & training participants in over 30 countries
    Training | Certification | Education | Research

Honourable Dr. G. N. Singh, Drug Controller General of India presented a Momento by our Director Mr. Syed S. Abbas & Principal Advisor Mr. Vinod Arora on the launch of our Computer System Validation (CSV) programme

IGMPI is conferred with ASSOCHAM Services Excellence Award 2017: Our Directors Mr Syed S. Abbas & Mrs Rafat Abedi, Chief Advisor Dr Mahesh Gupta, Advisor Mr Amitabh Srivastava are being honoured by the Chief Guest & Honorable Member of Parliament Dr. Udit Raj


New Alzheimer’s Drug Falls Short on Efficacy

New Alzheimer’s Drug Falls Short on Efficacy

New England Journal of Medicine (NEJM) recently published reports claiming that solanezumab, a monoclonal antibody-based treatment for Alzheimer’s disease developed by Eli Lilly that targets amyloid plaques, did not significantly slow cognitive decline.

According to research it is believed that Alzheimer’s disease is caused by the build-up of a sticky protein called beta-amyloid. According to this, the protein forms plaques in the brain that damage and eventually destroy brain cells. As per the new theory, Solanezumab was designed to reduce the level of soluble amyloid molecules before they aggregate.

In a study involving total of 2,129 patients with mild dementia due to Alzheimer’s disease, the treatment with Solanezumabdid have some favourable effects, and the major outcomes were-measured with a cognitive test called the Alzheimer’s Disease Assessment Scale-cognitive subscale–the researchers did not observe any statistically significant benefit compared with placebo.

The authors suggest that while it is not certain that this particular strategy or drug could be effective, it is possible that either not enough drug was administered or that the drug needs to be administered earlier in the disease course.

In otherongoing studies, solanezumab is being evaluated in presymptomatic patients at risk of Alzheimer’s disease. However, no major breakthrough is observed. Studies involving other Alzheimer’s drugs are also in development and being tested at higher doses.

“There is hope that one of the newer ongoing studies may result in an effective treatment for slowing the course of Alzheimer’s disease” said a researcher.